Nuvation Bio Announces Proposed Convertible Senior Notes Offering
Rhea-AI Summary
Nuvation Bio (NYSE: NUVB) plans an underwritten offering of $200 million Convertible Senior Notes due 2032, with a $30 million over-allotment option. The unsecured notes will pay semiannual interest and may be settled in cash, Class A common stock, or both upon conversion.
According to Nuvation Bio, net proceeds are expected to fund capped call transactions, fully repay its senior secured loan, and support general corporate purposes. Capped calls are intended to limit potential dilution or extra cash payments upon note conversion, subject to a cap.
Positive
- Planned $200 million convertible notes financing, plus $30 million over-allotment option
- Intent to fully repay existing senior secured loan with offering proceeds
- Capped call transactions designed to reduce potential share dilution on conversion
Negative
- Convertible notes may lead to future equity dilution for NUVB shareholders
- New debt will add interest obligations until any conversion, redemption or repurchase
- Hedging and derivative transactions may increase stock price volatility for NUVB shares and notes
News Market Reaction – NUVB
On the day this news was published, NUVB declined 10.06%, reflecting a significant negative market reaction. Argus tracked a peak move of +8.8% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $252M from the company's valuation, bringing the market cap to $2.25B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Conference appearance | Neutral | +0.2% | Jefferies Global Healthcare Conference fireside chat announcement and webcast details. |
| May 27 | Clinical data update | Positive | +1.1% | New quality-of-life data for IBTROZI from Phase 2 TRUST-II in ROS1+ NSCLC. |
| May 13 | Manufacturing collaboration | Positive | -1.3% | Thermo Fisher collaboration for U.S.-based manufacturing of IBTROZI to secure supply. |
| May 06 | Regulatory milestone | Positive | +4.3% | FDA acceptance of sNDA for IBTROZI with updated duration-of-response data. |
| May 05 | Investor conferences | Neutral | +4.3% | Participation in multiple May 2026 investor conferences with webcast access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent NUVB news has usually led to modest positive price moves, with one divergence on a partnership announcement.
Key Terms
convertible senior notes financial
capped call transactions financial
shelf registration statement regulatory
form s-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Notes will be general unsecured obligations of Nuvation Bio, with any interest payable semiannually in arrears and will mature on July 1, 2032, unless earlier converted, redeemed or repurchased. Upon conversion, Nuvation Bio will pay or deliver cash, shares of Nuvation Bio's Class A common stock, par value
Nuvation Bio expects to use the net proceeds from the Offering (i) to pay the cost of the capped call transactions described below, (ii) to repay in full all obligations under our senior secured loan agreement, and (iii) for general corporate purposes, which may include working capital, operating expenses, capital expenditures and general and administrative expenses.
In connection with the pricing of the Notes, Nuvation Bio expects to enter into capped call transactions with one or more of the underwriters or affiliates thereof and/or other financial institutions (the "Option Counterparties"). If the underwriters exercise their over-allotment option, Nuvation Bio expects to enter into additional capped call transactions. The capped call transactions will cover, subject to customary adjustments, the number of shares of Class A common stock initially underlying the Notes. The capped call transactions are expected generally to reduce the potential dilution to the Class A common stock upon any conversion of Notes and/or offset any cash payments Nuvation Bio is required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap.
In connection with establishing their initial hedges of the capped call transactions, Nuvation Bio expects the Option Counterparties or their respective affiliates will enter into various derivative transactions with respect to the Class A common stock concurrently with or shortly after the pricing of the Notes, including with certain investors in the Notes. This activity could increase (or reduce the size of any decrease in) the market price of the Class A common stock or the Notes at that time.
In addition, the Option Counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Class A common stock and/or purchasing or selling Class A common stock or other securities of Nuvation Bio in secondary market transactions following the pricing of the Notes and prior to the maturity of the Notes (and are likely to do so during the 40-trading day period beginning on the 41st scheduled trading day prior to the maturity date of the Notes, or, to the extent Nuvation Bio exercises the relevant election under the capped call transactions, following any repurchase, redemption or conversion of the Notes). This activity could also cause or avoid an increase or a decrease in the market price of the Class A common stock or the Notes which could affect a noteholder's ability to convert the Notes and, to the extent the activity occurs during any observation period related to a conversion of Notes, it could affect the number of shares, if any, and value of the consideration that a noteholder will receive upon conversion of its Notes.
The Notes are being offered pursuant to a "shelf" registration statement on Form S-3 (File No. 333-285621), including a base prospectus, that was previously filed by Nuvation Bio and automatically became effective under the rules of the Securities and Exchange Commission (the "SEC") on March 6, 2025. A preliminary prospectus supplement relating to the Offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the Offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue,
Jefferies LLC, Citigroup and Cantor Fitzgerald & Co. are acting as joint bookrunning managers for the Offering. RBC Capital Markets, LLC is acting as bookrunner for the Offering.
This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.
About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
Forward-Looking Statements
The information set forth in this press release contains certain "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the proposed Offering, including statements concerning the proposed and the anticipated completion, timing and size of the proposed Offering, the granting to the underwriters of a 30-day option to purchase additional Notes, the capped call transactions, the anticipated use of proceeds from the Offering, the repayment of our senior secured loan agreement, and the potential impact of the foregoing or related transactions on dilution to holders of the Class A common stock and the market price of the Class A common stock or the Notes or the conversion price of the Notes. These forward-looking statements are based on Nuvation Bio's current assumptions, expectations and beliefs and are subject to substantial risks, uncertainties, assumptions and changes in circumstances that may cause Nuvation Bio's actual results, performance or achievements to differ materially from those expressed or implied in any forward-looking statement. These risks include, but are not limited to the risks associated with market conditions and the satisfaction of customary closing conditions related to the proposed Offering, the risks associated with failing to satisfy the terms and conditions of repayment of our senior secured loan agreement, and the risks and uncertainties inherent in Nuvation Bio's business. Other risk factors include those that are discussed under the heading "Risk Factors" in Nuvation Bio's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and other filings made with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.
Media and Investor Contacts
Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com
Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-announces-proposed-convertible-senior-notes-offering-302810612.html
SOURCE Nuvation Bio, Inc.